echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > GSK and the U.S. mission review strong joint efforts, will work together deep into the pharmaceutical OTC industry.

    GSK and the U.S. mission review strong joint efforts, will work together deep into the pharmaceutical OTC industry.

    • Last Update: 2020-08-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On August 18, U.S. Mission Reviews and GlaxoSmithKly Consumer Health Products China (GSK) announced a comprehensive and in-depth cooperation, and the two sides will work together to deepen the pharmaceutical OTC industry.
    including the construction of local life services based on the pharmaceutical O2O model, to provide consumers with a richer product range, more convenient drug purchase services and so on.
    OTC is short for over-the-counter drugs and is generally a drug that consumers can judge, purchase and use at their discretion.
    data, the global OTC drug market as a whole is on the rise in 2013-2018, with a size of about $122 billion in 2019.
    expects the global OTC market to continue to grow by 2020-2025, reaching $162 billion by 2025.
    In China, in recent years, the domestic OTC industry market size has continued to grow, according to the China Pharmaceutical Association data, the industry's annual compound growth rate of 7.7%, far higher than the global average growth rate, China's OTC market development potential is huge.
    industry expects demand for OTC to continue to grow as people's consumption levels escalate and health awareness increases.
    that by 2020, China's OTC drug market size or will lead the world, and in the future to expand to 600 billion to 800 billion yuan of market size.
    OTC products have brand consumer goods attributes, not affected by policy collection, in the face of a considerable market blue sea, OTC market competition is also very fierce, the business model of enterprises to continue to explore innovation.
    it is understood that the U.S. mission review and GSK's comprehensive and in-depth cooperation will be carried out from three aspects.
    , to serve consumers as the core, build online supply.
    through the U.S. group of consumer demand big data analysis technology, the integration of both sides of the advantages of resources, to help offline traditional pharmacies embrace the new retail medicine, to achieve the physical pharmacy stores online operation and management.
    this move will provide the vast number of users across the country with better quality, more complete categories, more convenient drug purchase experience.
    Second, through online and offline integrated life service scene marketing, to help GSK's many popular brands and platform full-scene ecological combination, to cultivate consumers in a variety of scenarios on GSK products.
    new channels to help GSK bring new growth opportunities and create incremental markets.
    Third, through more online marketing tools, GSK from activities, users, terminal pharmacies and other different dimensions of the accumulation of digital assets, and form a real-time, visual data analysis, for brand marketing delivery and supply strategy to provide scientific optimization guidance.
    help traditional pharmaceutical companies accelerate the pace of digital marketing and foster innovative marketing concepts.
    in the post-epidemic era, with the help of the power of Internet platform, so that the pharmaceutical OTC industry ushered in new development.
    In the industry's view, this year by the impact of a special period, "Internet plus" mode constantly opened, in which the penetration rate of "Internet plus medicine" is constantly improving, quickly into people's lives, gradually change people's consumption habits.
    U.S. mission reviews and GSK this joint, or for the OTC industry to explore a new direction of development.
    , GSK is a large, research and development-based multinational pharmaceutical company in the world.
    products dominate the treatment of antibiotics, central nervous system, respiratory and digestive systems.
    GSK's China business is mainly focused on prescription drugs, vaccines and other fields.
    2019 GSK announces the completion of a deal with Pfizer to consolidate its consumer health products business and form a global joint venture.
    GSK Consumer Health Products China will strengthen its leading position in pain management, respiratory health, nutritional supplements, and therapeutic oral health care.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.